AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal ganglion cell loss in rats
Life Science Alliance · 2025
DOI: 10.26508/lsa.202403087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2025. Verfasst von Ge Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Tohoku University Graduate School of Medicine, Miyagi, Japan. Hauptthemen laut MEDLINE: Retinal Ganglion Cells, Endothelin-1, Endothelins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Science and Technology Agency, MEXT | Japan Society for the Promotion of Science, RHOTO Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
Dysfunction of ocular blood flow (BF) is believed to be one of the causes of glaucomatous pathology. However, whether this dysfunction is indeed a cause or is actually a consequence of optic nerve degeneration remains controversial. Here, we established a new animal model of chronic BF reduction in the retina to mimic glaucoma. We found that retinal BF in rats, as measured with laser speckle flowgraphy, was significantly reduced 3 wk after an intravitreal injection of AAV2-human endothelin-1 (AAV2-hEDN1). The number of retinal ganglion cells was also reduced in rats that received AAV2-hEDN1 injection. Immunostaining signals for GFAP and the endothelin-B receptor were enhanced in the rat retinas after AAV2-hEDN1 injection. Moreover, mRNA levels of Ripk1 / Ripk3 and Tnf in the retina increased, and glutathione levels in the aqueous humor decreased in rats that received AAV2-hEDN1 injection. Our findings demonstrate that endothelin-induced chronic retinal BF reduction leads to increased astrocyte activation and oxidative stress, which in turn induces retinal ganglion cell necroptosis. This suggests that methods to improve ocular BF have potential as novel therapies for glaucoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
- Department of Advanced Ophthalmic Medicine, Tohoku University Graduate School of Medicine, Miyagi, Japan.
- Laboratory of Biomedical and Analytical Sciences, Faculty of Pharmaceutial Science, Teikyo University, Tokyo, Japan.
- Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Miyagi, Japan.
- Department of Ophthalmology, Tohoku University Graduate School of Medicine, Miyagi, Japan toru.nakazawa.e1@tohoku.ac.jp.
- Department of Retinal Disease Control, Tohoku University Graduate School of Medicine, Miyagi, Japan.
ORCID-Profile: Kota Sato, Toru Nakazawa
Förderung
- MEXT | Japan Science and Technology Agency
- MEXT | Japan Society for the Promotion of Science
- RHOTO Pharmaceutical Co., Ltd.
Zitieren
APA
Shi, G., Sato, K., Takahashi, N., Ohno-Ohishi, M., Murayama, N., Yamaguchi, C., Saigusa, D., & Nakazawa, T. (2025). AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal ganglion cell loss in rats. Life Science Alliance. https://doi.org/10.26508/lsa.202403087
Vancouver
Shi G, Sato K, Takahashi N, Ohno-Ohishi M, Murayama N, Yamaguchi C, et al. AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal ganglion cell loss in rats. Life Science Alliance. 2025. doi:10.26508/lsa.202403087
BibTeX
@article{Shi2025,
author = {Shi, Ge and Sato, Kota and Takahashi, Nana and Ohno-Ohishi, Michiko and Murayama, Namie and Yamaguchi, Chiaki and Saigusa, Daisuke and Nakazawa, Toru},
title = {AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal ganglion cell loss in rats},
journal = {Life Science Alliance},
year = {2025},
doi = {10.26508/lsa.202403087}
}
EUVIMED